Improved Stability of Rifampicin in the Presence of Gastric-Resistant Isoniazid Microspheres in Acidic Media

Overview

Journal Pharmaceutics

Publisher MDPI

Date 2020 Mar 11

PMID 32151053

Citations 6

Authors

Chiluba Mwila

Roderick B Walker

Affiliations

Soon will be listed here.

Abstract

The degradation of rifampicin (RIF) in an acidic medium to form 3-formyl rifamycin SV, a poorly absorbed compound, is accelerated in the presence of isoniazid, contributing to the poor bioavailability of rifampicin. This manuscript presents a novel approach in which isoniazid is formulated into gastric-resistant sustained-release microspheres and RIF into microporous floating sustained-release microspheres to reduce the potential for interaction between RIF and isoniazid (INH) in an acidic environment. Hydroxypropyl methylcellulose acetate succinate and Eudragit L100 polymers were used for the manufacture of isoniazid-loaded gastric-resistant sustained-release microspheres using an o/o solvent emulsification evaporation approach. Microporous floating sustained-release microspheres for the delivery of rifampicin in the stomach were manufactured using emulsification and a diffusion/evaporation process. The design of experiments was used to evaluate the impact of input variables on predefined responses or quality attributes of the microspheres. The percent degradation of rifampicin following 12 h dissolution testing in 0.1 M HCl pH 1.2 in the presence of isoniazid gastric-resistant sustained-release microspheres was only 4.44%. These results indicate that the degradation of rifampicin in the presence of isoniazid in acidic media can be reduced by encapsulation of both active pharmaceutical ingredients to ensure release in different segments of the gastrointestinal tract, potentially improving the bioavailability of rifampicin.

Citing Articles

New Ionic Liquid Forms of Antituberculosis Drug Combinations for Optimized Stability and Dissolution.

Rasmy H, Abouelmagd S, Ibrahim E AAPS PharmSciTech. 2025; 26(1):27.

PMID: 39779636 DOI: 10.1208/s12249-024-03023-1.

Development and Validation of a UPLC-MS/MS Method for Therapeutic Drug Monitoring, Pharmacokinetic and Stability Studies of First-Line Antituberculosis Drugs in Urine.

Abouzid M, Kosicka-Noworzyn K, Karazniewicz-Lada M, Rao P, Modi N, Xie Y Molecules. 2024; 29(2).

PMID: 38257250 PMC: 10818978. DOI: 10.3390/molecules29020337.

Development and Validation of LC-MS/MS Method for the Determination of 1-Methyl-4-Nitrosopiperazine (MNP) in Multicomponent Products with Rifampicin-Analytical Challenges and Degradation Studies.

Witkowska A, Wolczynska A, Lis-Cieplak A, Stolarczyk E Molecules. 2023; 28(21).

PMID: 37959824 PMC: 10648194. DOI: 10.3390/molecules28217405.

Advanced drug delivery and therapeutic strategies for tuberculosis treatment.

Nair A, Greeny A, Nandan A, Sah R, Jose A, Dyawanapelly S J Nanobiotechnology. 2023; 21(1):414.

PMID: 37946240 PMC: 10634178. DOI: 10.1186/s12951-023-02156-y.

Development and Evaluation of Floating Microspheres of Anticonvulsant Drug by 3 Full Factorial Design.

Bhise M, Shukla K, Jain S, Bhajipale N, Sudke S, Burakle P Turk J Pharm Sci. 2022; 19(5):595-602.

PMID: 36317946 PMC: 9634442. DOI: 10.4274/tjps.galenos.2021.53050.

References

Jagtap Y, Bhujbal R, Ranade A, Ranpise N . Effect of various polymers concentrations on physicochemical properties of floating microspheres. Indian J Pharm Sci. 2013; 74(6):512-20. PMC: 3687920. DOI: 10.4103/0250-474X.110578. View

SENSI P, Maggi N, FURESZ S, Maffii G . Chemical modifications and biological properties of rifamycins. Antimicrob Agents Chemother (Bethesda). 1966; 6:699-714. View

Agrawal S, Ashokraj Y, Bharatam P, Pillai O, Panchagnula R . Solid-state characterization of rifampicin samples and its biopharmaceutic relevance. Eur J Pharm Sci. 2004; 22(2-3):127-44. DOI: 10.1016/j.ejps.2004.02.011. View

Ozdemir N, Ordu S, Ozkan Y . Studies of floating dosage forms of furosemide: in vitro and in vivo evaluations of bilayer tablet formulations. Drug Dev Ind Pharm. 2000; 26(8):857-66. DOI: 10.1081/ddc-100101309. View

Chandran S, Asghar L, Mantha N . Design and Evaluation of Ethyl Cellulose Based Matrix Tablets of Ibuprofen with pH Modulated Release Kinetics. Indian J Pharm Sci. 2011; 70(5):596-602. PMC: 3038283. DOI: 10.4103/0250-474X.45397. View

Kilicarslan M, Baykara T . The effect of the drug/polymer ratio on the properties of the verapamil HCl loaded microspheres. Int J Pharm. 2003; 252(1-2):99-109. DOI: 10.1016/s0378-5173(02)00630-0. View

Stevens R, Gray V, Dorantes A, Gold L, Pham L . Scientific and regulatory standards for assessing product performance using the similarity factor, f2. AAPS J. 2015; 17(2):301-6. PMC: 4365094. DOI: 10.1208/s12248-015-9723-y. View

Kang F, Singh J . Effect of additives on the release of a model protein from PLGA microspheres. AAPS PharmSciTech. 2004; 2(4):30. PMC: 2784845. DOI: 10.1208/pt020430. View

Singh H, Bhandari R, Kaur I . Encapsulation of Rifampicin in a solid lipid nanoparticulate system to limit its degradation and interaction with Isoniazid at acidic pH. Int J Pharm. 2013; 446(1-2):106-11. DOI: 10.1016/j.ijpharm.2013.02.012. View

10.

Singh S, Mariappan T, Shankar R, Sarda N, Singh B . A critical review of the probable reasons for the poor variable bioavailability of rifampicin from anti-tubercular fixed-dose combination (FDC) products, and the likely solutions to the problem. Int J Pharm. 2001; 228(1-2):5-17. DOI: 10.1016/s0378-5173(01)00754-2. View

11.

Wilson B, Babubhai P, Sajeev M, Jenita J, Priyadarshini S . Sustained release enteric coated tablets of pantoprazole: formulation, in vitro and in vivo evaluation. Acta Pharm. 2013; 63(1):131-40. DOI: 10.2478/acph-2013-0002. View

12.

Barmpalexis P, Kanaze F, Georgarakis E . Developing and optimizing a validated isocratic reversed-phase high-performance liquid chromatography separation of nimodipine and impurities in tablets using experimental design methodology. J Pharm Biomed Anal. 2009; 49(5):1192-202. DOI: 10.1016/j.jpba.2009.03.003. View

13.

Pund S, Joshi A, Vasu K, Nivsarkar M, Shishoo C . Gastroretentive delivery of rifampicin: in vitro mucoadhesion and in vivo gamma scintigraphy. Int J Pharm. 2011; 411(1-2):106-12. DOI: 10.1016/j.ijpharm.2011.03.048. View

14.

Pandya N, Pandya M, Bhaskar V . Preparation and in vitro Characterization of Porous Carrier-Based Glipizide Floating Microspheres for Gastric Delivery. J Young Pharm. 2011; 3(2):97-104. PMC: 3122053. DOI: 10.4103/0975-1483.80292. View

15.

Ye Z, Rombout P, Remon J, Vervaet C, Van den Mooter G . Correlation between the permeability of metoprolol tartrate through plasticized isolated ethylcellulose/hydroxypropyl methylcellulose films and drug release from reservoir pellets. Eur J Pharm Biopharm. 2007; 67(2):485-90. DOI: 10.1016/j.ejpb.2007.02.010. View

16.

Viswanathan N, Thomas P, Pandit J, Kulkarni M, Mashelkar R . Preparation of non-porous microspheres with high entrapment efficiency of proteins by a (water-in-oil)-in-oil emulsion technique. J Control Release. 1999; 58(1):9-20. DOI: 10.1016/s0168-3659(98)00140-0. View

17.

Bhise S, More A, Malayandi R . Formulation and in vitro evaluation of rifampicin loaded porous microspheres. Sci Pharm. 2010; 78(2):291-302. PMC: 3002794. DOI: 10.3797/scipharm.0910-09. View

18.

Shishoo C, Shah S, Rathod I, Savale S, Vora M . Impaired bioavailability of rifampicin in presence of isoniazid from fixed dose combination (FDC) formulation. Int J Pharm. 2001; 228(1-2):53-67. DOI: 10.1016/s0378-5173(01)00831-6. View

19.

Sankar R, Sharda N, Singh S . Behavior of decomposition of rifampicin in the presence of isoniazid in the pH range 1-3. Drug Dev Ind Pharm. 2003; 29(7):733-8. DOI: 10.1081/ddc-120021772. View

20.

Agrawal S, Singh I, Kaur K, Bhade S, Kaul C, Panchagnula R . Comparative bioavailability of rifampicin, isoniazid and pyrazinamide from a four drug fixed dose combination with separate formulations at the same dose levels. Int J Pharm. 2004; 276(1-2):41-9. DOI: 10.1016/j.ijpharm.2004.02.019. View